You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Medtronic
McKesson
Dow

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-228

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for TAK-228?

TAK-228 is an investigational drug.

There have been 347 clinical trials for TAK-228. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are thirty-two US patents protecting this investigational drug and three hundred and twenty international patents.

Recent Clinical Trials for TAK-228
TitleSponsorPhase
Japan Expanded Access Program With Lanadelumab for Japanese Patients With Hereditary AngioedemaTakedaPhase 3
A Study of TAK-536 in Pediatric Participants From 2 to Less Than 6 Years of Age With HypertensionTakedaPhase 3
A Study of Icatibant (TAK-667) in Japanese Children and Adolescents With Acute Attacks of Hereditary AngioedemaTakedaPhase 3

See all TAK-228 clinical trials

Clinical Trial Summary for TAK-228

Top disease conditions for TAK-228
Top clinical trial sponsors for TAK-228

See all TAK-228 clinical trials

US Patents for TAK-228

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-228   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
TAK-228   Start Trial Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN)   Start Trial
TAK-228   Start Trial Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC (La Jolla, CA)   Start Trial
TAK-228   Start Trial Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-228

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-228 Australia AU2014348657 2033-11-13   Start Trial
TAK-228 Australia AU2017245411 2033-11-13   Start Trial
TAK-228 Australia AU2019246853 2033-11-13   Start Trial
TAK-228 Brazil BR112016010716 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Medtronic
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.